Anthony Bowen is an Infectious Disease physician affiliated with Aaron Diamond AIDS Research Center. OpenAlex indexes 49 publications with 3,283 citations (h-index 21).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
180 Fort Washington Ave
Harkness Pavilion 6th Floor
New York, NY 10032
Telephone
212-305-3174Provider last certified this registry record 3 Sept 2025.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
41.7%Statin13.2%Atorvastatin Calcium100%Part D<11 patientsACE inhibitor12.5%Lisinopril100%Part D<11 patients+ 2 more classes in this area
Anti-infectives
27.8%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor19.4%Juluca61%Tivicay39%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor8.3%Triumeq100%Part D<11 patientsMetabolism & gastrointestinal
15.3%Biguanide (metformin)7.6%Metformin Hcl100%Part D<11 patientsGLP-1 receptor agonist7.6%Trulicity100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Elucidating the impact of immune imprinting on SARS-CoV-2 variant vaccination strategies using a humanized mouse model
Columbia University Health Sciences
FY2026$193,644K08AI180347 - Elucidating the impact of immune imprinting on SARS-CoV-2 variant vaccination strategies using a humanized mouse model
Columbia University Health Sciences
FY2025$193,644K08AI180347 - Elucidating the impact of immune imprinting on SARS-CoV-2 variant vaccination strategies using a humanized mouse model
Columbia University Health Sciences
FY2024$193,644K08AI180347
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- LP.8.1-directed COVID-19 mRNA vaccines durably boost neutralizing antibodies and mitigate ancestral immune imprinting
bioRxiv (Cold Spring Harbor Laboratory)
2026 - KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2
The Lancet Infectious Diseases
2025 - Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants
bioRxiv (Cold Spring Harbor Laboratory)
2025
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”